Identification of Nedd9 as a TGF-β-Smad2/3 target gene involved in RANKL-Induced osteoclastogenesis by comprehensive analysis

PLoS ONE

Volumn 11, Issue 6, 2016, Pages

  Omata, Yasunori ^a   Nakamura, Shinya ^a   Koyama, Takuma ^a   Yasui, Tetsuro ^a   Hirose, Jun ^a   Izawa, Naohiro ^a   Matsumoto, Takumi ^a   Imai, Yuuki ^b   Seo, Sachiko ^c   Kurokawa, Mineo ^c   Tsutsumi, Shuichi ^d   Kadono, Yuho ^a   Morimoto, Chikao ^e   Aburatani, Hiroyuki ^d   Miyamoto, Takeshi ^a,f   Tanaka, Sakae ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e JUNTENDO UNIVERSITY   (Japan)

^f KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1A; HISTONE H3; HISTONE H3K27; HISTONE H3K4; OSTEOCLAST DIFFERENTIATION FACTOR; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD6 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; HISTONE; NEDD9 PROTEIN, MOUSE; PROTEIN BINDING; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CDKN1A GENE; CELL DIFFERENTIATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; GENE; GENE IDENTIFICATION; GENETIC REGULATION; HISTONE MODIFICATION; MALE; MOUSE; NEDD9 GENE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; PDGFB GENE; PROMOTER REGION; PROTEIN FUNCTION; SERPINE1 GENE; SKI GENE; SMAD6 GENE; SMAD7 GENE; TMEPAI GENE; UPREGULATION; ANIMAL; DRUG EFFECTS; DRUG THERAPY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; KNOCKOUT MOUSE; METABOLISM; OSTEOLYSIS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; BONE RESORPTION; CELL DIFFERENTIATION; EPIGENESIS, GENETIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HISTONES; MALE; MICE; MICE, KNOCKOUT; OSTEOCLASTS; PROTEIN BINDING; RANK LIGAND; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 84976530702     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0157992     Document Type: Article

References (33)

1. Tanaka S. Signaling axis in osteoclast biology and therapeutic targeting in the RANKL/RANK/OPG system. Am J Nephrol. 2007; 27(5):466-78. doi:10.1159/000106484 PMID: 17652963.
2. Yasui T, Kadono Y, Nakamura M, Oshima Y, Matsumoto T, Masuda H, et al. Regulation of RANKLinduced osteoclastogenesis by TGF-beta through molecular interaction between Smad3 and Traf6. J Bone Miner Res. 2011; 26(7):1447-56. doi:10.1002/jbmr.357 PMID: 21305609.
3. Omata Y, Yasui T, Hirose J, Izawa N, Imai Y, Matsumoto T, et al. Genomewide comprehensive analysis reveals critical cooperation between Smad and c-Fos in RANKL-induced osteoclastogenesis. J Bone Miner Res. 2015; 30(5):869-77. doi:10.1002/jbmr.2418 PMID: 25431176.
4. Janssens K, ten Dijke, P, Janssens S, Van Hul, W. Transforming growth factor-beta1 to the bone. Endocr Rev. 2005; 26(6):743-74. doi:10.1210/er.2004-0001 PMID: 15901668.
5. Tang SY, Alliston T. Regulation of postnatal bone homeostasis by TGFbeta. Bonekey Rep. 2013; 2:255. doi:10.1038/bonekey.2012.255 PMID: 24404376; PubMed Central PMCID: PMCPMC3722719.
6. Ikushima H, Miyazono K. TGF-beta signal transduction spreading to a wider field: A broad variety of mechanisms for context-dependent effects of TGF-beta. Cell Tissue Res. 2012; 347(1):37-49. doi:10.1007/s00441-011-1179-5PMID: 21618142.
7. Massague J, Attisano L, Wrana JL. The TGF-beta family and its composite receptors. Trends Cell Biol. 1994; 4(5):172-8. PMID: 14731645.
8. Li MO, Flavell RA. TGF-beta: A master of all T cell trades. Cell. 2008; 134(3):392-404. doi:10.1016/j.cell.2008.07.025PMID: 18692464; PubMed Central PMCID: PMCPMC3677783.
9. Graff JM, Bansal A, Melton DA. Xenopus Mad proteins transduce distinct subsets of signals for the TGF beta superfamily. Cell. 1996; 85(4):479-87. PMID: 8653784.
10. Huang W, Drissi MH, O'Keefe RJ, Schwarz EM. A rapid multiparameter approach to study factors that regulate osteoclastogenesis: demonstration of the combinatorial dominant effects of TNF- Alpha and TGF-ss in RANKL-mediated osteoclastogenesis. Calcif Tissue Int. 2003; 73(6):584-93. doi:10.1007/s00223-003-0059-8PMID: 14517717.
11. Margueron R, Trojer P, Reinberg D. The key to development: Interpreting the histone code? Curr Opin Genet Dev. 2005; 15(2):163-76. doi:10.1016/j.gde.2005.01.005 PMID: 15797199.
12. Zhang Y, Reinberg D. Transcription regulation by histone methylation: Interplay between different covalent modifications of the core histone tails. Genes Dev. 2001; 15(18):2343-60. doi:10.1101/gad.927301PMID: 11562345.
13. Strahl BD, Ohba R, Cook RG, Allis CD. Methylation of histone H3 at lysine 4 is highly conserved and correlates with transcriptionally active nuclei in Tetrahymena. Proc Natl Acad Sci U S A. 1999; 96 (26):14967-72. PMID: 10611321; PubMed Central PMCID: PMCPMC24756.
14. Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, Cuff J, et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell. 2006; 125(2):315-26. doi:10.1016/j.cell.2006.02.041 PMID: 16630819.
15. Yasui T, Hirose J, Tsutsumi S, Nakamura K, Aburatani H, Tanaka S. Epigenetic regulation of osteoclast differentiation: possible involvement of Jmjd3 in the histone demethylation of Nfatc1. Journal of bone and mineral research: The official journal of the American Society for Bone and Mineral Research. 2011; 26(11):2665-71. doi:10.1002/jbmr.464 PMID: 21735477.
16. Giresi PG, Lieb JD. Isolation of active regulatory elements from eukaryotic chromatin using FAIRE (Formaldehyde Assisted Isolation of Regulatory Elements). Methods. 2009; 48(3):233-9. doi:10.1016/j.ymeth.2009.03.003 PMID: 19303047; PubMed Central PMCID: PMCPMC2710428.
17. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. doi:10.1073/pnas.0506580102 PMID: 16199517; PubMed Central PMCID: PMCPMC1239896.
18. Minegishi M, Tachibana K, Sato T, Iwata S, Nojima Y, Morimoto C. Structure and function of Cas-L, a 105-kD Crk- Associated substrate-related protein that is involved in beta 1 integrin-mediated signaling in lymphocytes. The Journal of experimental medicine. 1996; 184(4):1365-75. PMID: 8879209; PubMed Central PMCID: PMC2192828.
19. Tikhmyanova N, Little JL, Golemis EA. CAS proteins in normal and pathological cell growth control. Cell Mol Life Sci. 2010; 67(7):1025-48. doi:10.1007/s00018-009-0213-1 PMID: 19937461; PubMed Central PMCID: PMCPMC2836406.
20. Tornillo G, Defilippi P, Cabodi S. Cas proteins: dodgy scaffolding in breast cancer. Breast Cancer Res. 2014; 16(5):443. PMID: 25606587; PubMed Central PMCID: PMCPMC4384296.
21. Law SF, Zhang YZ, Klein-Szanto AJ, Golemis EA. Cell cycle-regulated processing of HEF1 to multiple protein forms differentially targeted to multiple subcellular compartments. Mol Cell Biol. 1998; 18 (6):3540-51. PMID: 9584194; PubMed Central PMCID: PMCPMC108935.
22. Seo S, Asai T, Saito T, Suzuki T, Morishita Y, Nakamoto T, et al. Crk- Associated substrate lymphocyte type is required for lymphocyte trafficking and marginal zone B cell maintenance. J Immunol. 2005; 175 (6):3492-501. PMID: 16148091.
23. Shagisultanova E, Gaponova AV, Gabbasov R, Nicolas E, Golemis EA. Preclinical and clinical studies of the NEDD9 scaffold protein in cancer and other diseases. Gene. 2015; 567(1):1-11. doi:10.1016/j.gene.2015.04.086 PMID: 25967390; PubMed Central PMCID: PMCPMC4458429.
24. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, et al. High-resolution profiling of histone methylations in the human genome. Cell. 2007; 129(4):823-37. doi:10.1016/j.cell.2007.05.009 PMID: 17512414.
25. Guenther MG, Levine SS, Boyer LA, Jaenisch R, Young RA. A chromatin landmark and transcription initiation at most promoters in human cells. Cell. 2007; 130(1):77-88. doi:10.1016/j.cell.2007.05.042 PMID: 17632057; PubMed Central PMCID: PMC3200295.
26. Schwartz YB, Pirrotta V. Polycomb silencing mechanisms and the management of genomic programmes. Nature reviews Genetics. 2007; 8(1):9-22. doi:10.1038/nrg1981PMID: 17173055.
27. Liu X, Elia AE, Law SF, Golemis EA, Farley J, Wang T. A novel ability of Smad3 to regulate proteasomal degradation of a Cas family member HEF1. EMBO J. 2000; 19(24):6759-69. doi:10.1093/emboj/19.24.6759 PMID: 11118211; PubMed Central PMCID: PMCPMC305889.
28. Zheng M, McKeown-Longo PJ. Regulation of HEF1 expression and phosphorylation by TGF-beta 1 and cell adhesion. J Biol Chem. 2002; 277(42):39599-608. doi:10.1074/jbc.M202263200 PMID: 12189134.
29. Morimoto K, Tanaka T, Nitta Y, Ohnishi K, Kawashima H, Nakatani T. NEDD9 crucially regulates TGFbeta- Triggered epithelial-mesenchymal transition and cell invasion in prostate cancer cells: Involvement in cancer progressiveness. Prostate. 2014; 74(8):901-10. doi:10.1002/pros.22809 PMID: 24728978.
30. Inamoto S, Iwata S, Inamoto T, Nomura S, Sasaki T, Urasaki Y, et al. Crk- Associated substrate lymphocyte type regulates transforming growth factor-beta signaling by inhibiting Smad6 and Smad7. Oncogene. 2007; 26(6):893-904. doi:10.1038/sj.onc.1209848 PMID: 16909115.
31. Katayose T, Iwata S, Oyaizu N, Hosono O, Yamada T, Dang NH, et al. The role of Cas-L/NEDD9 as a regulator of collagen-induced arthritis in a murine model. Biochemical and biophysical research communications. 2015; 460(4):1069-75. doi:10.1016/j.bbrc.2015.03.156 PMID: 25847598.
32. Miyagishi M, Taira K. Strategies for generation of an siRNA expression library directed against the human genome. Oligonucleotides. 2003; 13(5):325-33. doi:10.1089/154545703322617005 PMID: 15000823.
33. Miyagishi M, Taira K. RNAi expression vectors in mammalian cells. Methods Mol Biol. 2004; 252:483-91. doi:10.1385/1-59259-746-7:483 PMID: 15017073.